.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Merck
Cipla
Teva
McKinsey
Daiichi Sankyo
Cantor Fitzgerald
Novartis
Fuji

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,842,714

« Back to Dashboard

Which drugs does patent 7,842,714 protect, and when does it expire?


Patent 7,842,714 protects ACUVAIL and is included in one NDA. There has been one Paragraph IV challenge on Acuvail.

This patent has forty patent family members in twenty countries.

Summary for Patent: 7,842,714

Title:Ketorolac tromethamine compositions for treating ocular pain
Abstract:The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
Inventor(s): Farnes; Eldon Q. (Laguna Beach, CA), Attar; Mayssa (Placentia, CA), Schiffman; Rhett M. (Laguna Beach, CA), Chang; Chin-Ming (Tustin, CA), Graham; Richard S. (Irvine, CA), Welty; Devin F. (Foothill Ranch, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/396,131
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
ACUVAIL
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC022427-001Jul 22, 2009ATRXYesYes7,842,714► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,842,714

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,192,571Ketorolac tromethamine compositions for treating or preventing ocular pain► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,842,714

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2566162► Subscribe
Hong Kong1149212► Subscribe
HungaryE027102► Subscribe
Israel207925► Subscribe
European Patent Office2473157► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Cipla
Express Scripts
Dow
Baxter
US Army
Cantor Fitzgerald
Cerilliant
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot